Sales and Marketing

Showing 15 posts of 11526 posts found.

Merck’s problems deepen as MHRA reveals investigation

September 8, 2005 Sales and Marketing

The controversy around the withdrawal of Vioxx has taken a new twist with news its manufacturer is being investigated for …

New RA drug from BMS gains recommendation

September 7, 2005 Sales and Marketing

A new treatment for rheumatoid arthritis from Bristol-Myers Squibb has received recommendation approval from an FDA committee, bringing it one …

$1 billion Cialis closing on Viagra

September 6, 2005 Sales and Marketing

Erectile dysfunction drug Cialis has achieved cumulative sales of $1 billion and is closing the gap on Pfizer's market leader …

All new product marketing to be pre-vetted in UK

September 2, 2005 Medical Communications, Sales and Marketing

Advertising and marketing materials for all new products are to be vetted by the UK regulator for the accuracy of …

Takeda’s dependence-free sleeping pill approved

September 2, 2005 Research and Development, Sales and Marketing

A new sleeping pill which patients cannot abuse or become dependent on has been approved in the US.Takeda's Rozerem (ramelteon) …

Schering’s new low-dose contraceptive approved in Netherlands

August 19, 2005 Sales and Marketing

Yasminelle, a new low-dose oral contraceptive from Schering has received its first European marketing approval in the Netherlands. The country …

Global giant VNU acquires IMS Health for $7 billion

August 17, 2005 Sales and Marketing

Dutch media, consumer and marketing information group VNU has bought IMS Health for $7 billion, as it looks to expand …

FDA approves Diovan for cardiovascular indication

August 16, 2005 Sales and Marketing

Novartis' biggest selling drug Diovan has received US approval for a new indication, as it strives to bolster its position …

Celebrex approved for new arthritis indication

August 8, 2005 Sales and Marketing

Celebrex has received US approval for a new indication as Pfizer looks to revive tumbling sales of its flagship COX- …

Teva’s modest sales growth driven by MS treatment

August 4, 2005 Sales and Marketing

Teva Pharmaceuticals, the world's number one generics manufacturer, has posted modest second quarter results driven by its patent-protected multiple sclerosis …
The Gateway to Local Adoption Series

Latest content